Recommended Topic Related To:

Dysport

"Feb. 8, 2011 -- Facelifts, breast augmentations, tummy tucks, and other cosmetic plastic surgery procedures have rebounded sharply along with an uptick in the U.S. economy, according to a new report.

The American Society of Plastic Su"...

Dysport

Dysport Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Dysport for Injection (abobotulinumtoxinA), also called botulinum toxin type A, is made from the bacteria that causes botulism and is used to treat cervical dystonia (severe spasms in the neck muscles). It is also used to temporarily lessen the appearance of facial wrinkles. Common side effects include muscle weakness near where the medicine was injected; bruising, bleeding, pain, redness, or swelling where the injection was given; headache, muscle pain or stiffness, neck or back pain, fever, cough, sore throat, runny nose, flu symptoms, dizziness, drowsiness, tired feeling, nausea, diarrhea, stomach pain, loss of appetite, dry mouth, dry eyes, ringing in your ears, increased sweating in areas other than the underarms, itchy or watery eyes, increased sensitivity to light, or eyelid swelling or bruising.

The recommended initial dose of Dysport for the treatment of cervical dystonia is 500 Units given intramuscularly as a divided dose among affected muscles. The dose of Dysport for the treatment of glabellar lines (the vertical lines between the eyebrows) is 50 Units given intramuscularly in five equal aliquots of 10 Units each to achieve clinical effect. Dysport may interact with cold or allergy medicines, muscle relaxers, sleeping pills, bronchodilators, bladder or urinary medicines, irritable bowel medicines, or injected antibiotics. Tell your doctor all medications and supplements you use. During pregnancy, Dysport should be used only if prescribed. It is unknown if Dysport passes into breast milk. Consult your doctor before breastfeeding.

Our Dysport for Injection (abobotulinumtoxinA) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

Dysport in Detail - Patient Information: Side Effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; feeling like you might pass out; swelling of your face, lips, tongue, or throat.

The botulinum toxin contained in Dysport can spread to other body areas beyond where it was injected. This has caused serious life-threatening side effects in some people receiving botulism toxin injections, even for cosmetic purposes.

Call your doctor at once if you have any of these serious side effects, some of which can occur up to several weeks after an injection:

  • trouble breathing, talking, or swallowing;
  • hoarse voice, drooping eyelids;
  • problems with vision;
  • unusual or severe muscle weakness (especially in a body area that was not injected with the medication);
  • loss of bladder control;
  • crusting or drainage from your eyes;
  • severe skin rash or itching;
  • fast, slow, or uneven heartbeats; or
  • chest pain or heavy feeling, pain spreading to the arm or shoulder, general ill feeling.

Less serious side effects may include:

  • muscle weakness near where the medicine was injected;
  • bruising, bleeding, pain, redness, or swelling where the injection was given;
  • headache, muscle pain or stiffness, neck or back pain;
  • fever, cough, sore throat, runny nose, flu symptoms,
  • dizziness, drowsiness, tired feeling;
  • nausea, diarrhea, stomach pain, loss of appetite;
  • dry mouth, dry eyes, ringing in your ears;
  • increased sweating in areas other than the underarms;
  • itchy or watery eyes, increased sensitivity to light; or
  • eyelid swelling or bruising.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Dysport (Abobotulinumtoxin A Injection) »

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Dysport FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

The following adverse reactions to Dysport are discussed in greater detail in other sections of the labeling.

Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other trials and may not reflect the rates observed in clinical practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating incidence rates.

Cervical Dystonia

The data described below reflect exposure to Dysport in 357 cervical dystonia patients in 6 studies. Of these, two studies were randomized, double-blind, single treatment, placebo controlled studies with subsequent optional open label treatment in which dose optimization (250 to 1000 Units per treatment) over the course of 5 treatment cycles was allowed.

The population was almost entirely Caucasian (99.2%) with a median age of 51 years (range 18-82 years). Most patients (86.6%) were less than 65 years of age; 58.4% were women.

Common Adverse Events

The most commonly reported adverse events (occurring in more than 5% of patients who received 500 Units of Dysport in the placebo controlled clinical trials) in cervical dystonia patients were muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation). Most adverse events were reported as mild or moderate in severity. Other than injection site reactions, most adverse events became noticeable about one week after treatment and lasted several weeks.

The rates of adverse events were higher in the combined controlled and open-label experience than in the placebo-controlled trials.

During the clinical studies, two patients ( < 1%) experienced adverse events leading to withdrawal. One patient experienced disturbance in attention, eyelid disorder, feeling abnormal and headache, and one patient experienced dysphagia.

Table 1 compares the incidence of the most frequent treatment-emergent adverse events (TEAEs) from a single treatment cycle of 500 Units of Dysport compared to placebo [see Clinical Studies].

Table 1: Most Common TEAEs ( > 5%) and Greater than Placebo: Double-blind Phase of Clinical Trials

System Organ Class
Preferred Term
Double-blind Phase
Dysport 500 Units
(N=173)
%
Placebo
(N=182)
%
Any TEAE 61 51
General disorders and administration site conditions 30 23
  Injection site discomfort 13 8
  Fatigue 12 10
  Injection site pain 5 4
Musculoskeletal and connective tissue disorders 30 18
  Muscular weakness 16 4
  Musculoskeletal pain 7 3
Gastrointestinal disorders 28 15
  Dysphagia 15 4
  Dry mouth 13 7
Nervous system disorders 16 13
  Headache 11 9
  Infections and infestations 13 9
Respiratory, thoracic and mediastinal disorders 12 8
  Dysphonia 6 2
  Eye Disordersa 7 2
aThe following preferred terms were reported: vision blurred, diplopia, visual acuity reduced, eye pain, eyelid disorder, accommodation disorder, dry eye, eye pruritus.

Dose-response relationships for common adverse events in a randomized multiple fixed-dose study in which the total dose was divided between two muscles (the sternocleidomastoid and splenius capitis) are shown in Table 2.

Table 2: Common TEAEs by Dose in Fixed-dose Study

System Organ Class
Preferred Term
Dysport Dose
Placebo 250 Units 500 Units 1000 Units
Any Adverse Event 30% 37% 65% 83%
Dysphagia 5% 21% 29% 39%
Dry Mouth 10% 21% 18% 39%
Muscular Weakness 0% 11% 12% 56%
Injection Site Discomfort 10% 5% 18% 22%
Dysphonia 0% 0% 18% 28%
Facial Paresis 0% 5% 0% 11%
Eye Disorders 0% 0% 6% 17%

Injection Site Reactions

Injection site discomfort and injection site pain were common adverse events following Dysport administration. These events were mainly of mild or moderate intensity.

Less Common Adverse Events

The following selected adverse events were reported less frequently ( < 5%).

Breathing Difficulties

Breathing difficulties were reported by approximately 3% of patients following Dysport administration and in 1% of placebo patients in clinical trials during the double-blind phase. These consisted mainly of dyspnea and were generally mild in intensity. The median time to onset from last dose of Dysport was approximately one week, and the median duration was approximately three weeks.

Other selected adverse events with incidences of less than 5% in the Dysport 500 Units group in the double-blind phase of clinical trials included dizziness in 3.5% of Dysport-treated subjects and 1% of placebo-treated subjects, and muscle atrophy in 1% of Dysport-treated subjects and in none of the placebo-treated subjects.

Laboratory Findings

Subjects treated with Dysport exhibited a small increase from baseline (0.23 mol/L) in mean blood glucose relative to placebo-treated subjects. This was not clinically significant among subjects in the development program but could be a factor in patients whose diabetes is difficult to control.

Electrocardiographic Findings

ECG measurements were only recorded in a limited number of subjects in an open-label study without a placebo or active control. This study showed a statistically significant reduction in heart rate compared to baseline, averaging about three beats per minute, observed thirty minutes after injection.

Glabellar Lines

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not be predictive of rates observed in practice.

In placebo-controlled clinical trials of Dysport, the most frequently reported adverse events ( ≥ 2%) following injection of Dysport were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis and nausea.

Table 3 reflects exposure to Dysport in 398 subjects aged 19 to 75 who were evaluated in the randomized, placebo-controlled clinical studies that assessed the use of Dysport for the temporary improvement in the appearance of glabellar lines [see Clinical Studies]. Adverse events of any cause were reported for 48% of the Dysport-treated subjects and 33% of the placebo-treated subjects. Treatment-emergent adverse events were generally mild to moderate in severity.

Table 3: Treatment-emergent Adverse Events with > 1% incidence

Adverse Events by Body System Dysport
n=398
(%)*
Placebo
n=496
(%)*
Any Treatment-emergent
  Adverse Event 191 (48) 163 (33)
Eye Disorders
  Eyelid Edema 8 (2) 0
  Eyelid Ptosis 6 (2) 1 ( < 1)
Gastrointestinal Disorders
  Nausea 6 (2) 5 (1)
General Disorders and Administration Site Conditions
  Injection Site Pain 11 (3) 8 (2)
  Injection Site Reaction 12 (3) 2 ( < 1)
Infections and Infestations
  Nasopharyngitis 38 (10) 21 (4)
  Upper Respiratory Tract Infection 12 (3) 9 (2)
  Sinusitis 8 (2) 6 (1)
Investigations
  Blood Urine Present 6 (2) 1 ( < 1)
Nervous System Disorders
  Headache 37 (9) 23 (5)
* Subjects who received treatment with placebo and Dysport are counted in both treatment columns.

In the overall safety database, where some subjects received up to twelve treatments with Dysport, adverse events were reported for 57% (1425/2491) of subjects. The most frequently reported of these adverse events were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).

Adverse events that emerged after repeated injections in 2-3% of the population included bronchitis, influenza, pharyngolaryngeal pain, cough, contact dermatitis, injection site swelling, and injection site discomfort.

The incidence of eyelid ptosis did not increase in the long-term safety studies with multiple re-treatments at intervals ≥ three months. The majority of eyelid ptosis events were mild to moderate in severity and resolved over several weeks. [see Injection Technique].

Post-marketing Spontaneous Reports

There is extensive post-marketing experience outside the U.S. for the treatment of glabellar lines. Adverse reactions are reported voluntarily from a population of uncertain size; thus, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure. The following adverse reactions have been identified during post-marketing use: vertigo, eyelid ptosis, diplopia, vision blurred, photophobia, dysphagia, nausea, injection site reaction, malaise, influenza-like illness, hypersensitivity, sinusitis, amyotrophy, burning sensation, facial paresis, dizziness, headache, hypoesthesia, erythema, and excessive granulation tissue.

Immunogenicity

As with all therapeutic proteins, there is a potential for immunogenicity.

The incidence of antibody formation is highly dependent on the sensitivity and specificity of the assay. In addition, the observed incidence of antibody positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies across products in this class may be misleading.

Cervical Dystonia

About 3% of subjects developed antibodies (binding or neutralizing) over time with Dysport treatment. The significance of these antibodies is unknown since in the presence of binding and neutralizing antibodies some patients may continue to experience clinical benefit.

Glabellar Lines

Testing for antibodies to Dysport was performed for 1554 subjects who had up to nine cycles of treatment. Two subjects (0.13%) tested positive for binding antibodies at baseline. Three additional subjects tested positive for binding antibodies after receiving Dysport treatment. None of the subjects tested positive for neutralizing antibodies.

Read the entire FDA prescribing information for Dysport (Abobotulinumtoxin A Injection) »

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.